<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856114</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0043</org_study_id>
    <secondary_id>NCI-2014-01033</secondary_id>
    <nct_id>NCT01856114</nct_id>
  </id_info>
  <brief_title>Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea</brief_title>
  <official_title>A Preliminary Study of Prophylactic Fentanyl Buccal Tablets (FBT) for Exercise Induced Breakthrough Dyspnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if fentanyl can change perception of&#xD;
      shortness of breath in cancer patients. Researchers also want to learn if the study drug can&#xD;
      help to improve your physical function. In this study, fentanyl will be compared to a&#xD;
      placebo.&#xD;
&#xD;
      Fentanyl is commonly used for treatment of cancer pain.&#xD;
&#xD;
      A placebo is not a drug. It looks like the study drug but is not designed to treat any&#xD;
      disease or illness. It is designed to be compared with a study drug to learn if the study&#xD;
      drug has any real effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the flip of a coin) to either receive fentanyl or placebo. You will have an equal chance&#xD;
      of being assigned to either group. Neither you nor the study staff will know if you are&#xD;
      receiving the study drug or the placebo. However, if needed for your safety, the study staff&#xD;
      will be able to find out what you are receiving.&#xD;
&#xD;
      Study Visit:&#xD;
&#xD;
      During your study visit, the study staff will collect information from your medical record&#xD;
      about your age, sex, race, disease type, how well you are able to perform the normal&#xD;
      activities of daily living, any drugs you are taking, and possible causes of shortness of&#xD;
      breath.&#xD;
&#xD;
      You will complete 2 questionnaires. One (1) of them will have questions about any breathing&#xD;
      symptoms you may be having, and the other asks about any other symptoms you may be having. It&#xD;
      should take about 10 minutes to complete these questionnaires.&#xD;
&#xD;
      The study staff will then record your vital signs (heart rate, breathing rate, and the level&#xD;
      of air breathed out using a measuring device that will be clipped onto your finger). You will&#xD;
      also be asked how hard it is to catch your breath and to rate your level of tiredness.&#xD;
&#xD;
      You will then walk back and forth in an indoor corridor for up to 6 minutes. This is called a&#xD;
      walk test. You may slow down, stop, and rest at any time you need to.&#xD;
&#xD;
      After that, you will sit down and rest for up to 1 hour. During this time, the study&#xD;
      drug/placebo will be prepared and you may be asked several times how hard it is to catch your&#xD;
      breath.&#xD;
&#xD;
      You will then be given a study drug/placebo tablet to put it in between your upper gum and&#xD;
      cheek. You will then wait for another 30 minutes, be asked about any side effects you may be&#xD;
      having, and repeat the walking test. Then the study staff will ask you again about any side&#xD;
      effects you may be having, your level of tiredness, and how hard it is to catch your breath.&#xD;
      Your vital signs will also be measured.&#xD;
&#xD;
      During each walk test, you will be asked 6 times how hard it is to catch your breath. How&#xD;
      often you stopped and for how long will be recorded. The total distance you walked will also&#xD;
      be recorded.&#xD;
&#xD;
      After each walk test, you will also be asked to complete 4 tests of your mental abilities,&#xD;
      including finger tapping, simple mathematics questions (addition, subtraction,&#xD;
      multiplication, division), recall of numbers, and recall of objects. It should take 15&#xD;
      minutes to complete these tests.&#xD;
&#xD;
      At the end of the study visit, you will fill out 1 questionnaire that asks if you think the&#xD;
      study drug/placebo is helping you, how satisfied you are with the study, and which treatment&#xD;
      you think you received. It should take about 5 minutes to complete the questionnaire.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      Your active participation in this study is over after you complete the last questionnaire.&#xD;
      You will be taken off study if intolerable side effects occur or if you are unable to follow&#xD;
      study directions.&#xD;
&#xD;
      Follow-Up:&#xD;
&#xD;
      Thirty (30) days after your study visit you will be called by the study staff and asked how&#xD;
      you are feeling and about any side effects you may be having. This call should last about 10&#xD;
      minutes.&#xD;
&#xD;
      This is an investigational study. Fentanyl is FDA approved and commercially available for the&#xD;
      treatment of pain. Its use to control shortness of breath is investigational.&#xD;
&#xD;
      Up to 20 participants will be enrolled in this study. All will take part at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2014</start_date>
  <completion_date type="Actual">December 4, 2019</completion_date>
  <primary_completion_date type="Actual">December 4, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dyspnea Numeric Rating Scale</measure>
    <time_frame>Baseline to 30 minutes</time_frame>
    <description>Our primary outcome was dyspnea intensity &quot;now&quot; using a dyspnea numeric rating scale that ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). Measured the mean difference between the baseline and second 6 minute walk test. 6 minute walk tests were carried out following guidelines from the American Thoracic Society.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea Borg Scale</measure>
    <time_frame>Baseline to 30 minutes</time_frame>
    <description>Assessed dyspnea using the 0-10 modified Dyspnea Borg Scale at baseline walk test and after second 6 minute walk test. The Borg scale ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). Measured the mean difference between the baseline walk test and second 6 minute walk test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walk Distance at 6 Minutes</measure>
    <time_frame>Baseline to 30 minutes</time_frame>
    <description>Measured the mean difference between the baseline walk test and second 6 minute walk test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>Fentanyl Buccal Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Fentanyl tablet to put in between upper gum and cheek. Study physician will determine the morphine equivalent daily dose (MEDD) in real time using standardized equianalgesic ratios. Based on clinical practice and similarly to the dose used for breakthrough pain, an FBT dose equivalent to 20-50% of the MEDD used. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Buccal Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Placebo tablet to put in between upper gum and cheek. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl Buccal Tablet</intervention_name>
    <description>Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.</description>
    <arm_group_label>Fentanyl Buccal Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Buccal Tablet</intervention_name>
    <description>Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.</description>
    <arm_group_label>Placebo Buccal Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.</description>
    <arm_group_label>Fentanyl Buccal Tablet</arm_group_label>
    <arm_group_label>Placebo Buccal Tablet</arm_group_label>
    <other_name>Surveys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of cancer with evidence of active disease&#xD;
&#xD;
          2. Breakthrough dyspnea, defined in this study as dyspnea on exertion with an average&#xD;
             intensity level &gt;/=3/10 on the numeric rating scale&#xD;
&#xD;
          3. Outpatient at MD Anderson Cancer Center seen by the Supportive Care Service, Thoracic&#xD;
             Medical Oncology or Cardiopulmonary Center&#xD;
&#xD;
          4. Ambulatory and able to walk with or without walking aid&#xD;
&#xD;
          5. On strong opioids with morphine equivalent daily dose of 60-130 mg for at least one&#xD;
             week, with stable (i.e. +/- 30%) regular dose over the last 24 hours&#xD;
&#xD;
          6. Karnofsky performance status &gt;/=50%&#xD;
&#xD;
          7. Age 18 or older&#xD;
&#xD;
          8. Able to complete study assessments&#xD;
&#xD;
          9. Must speak and understand English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dyspnea at rest &gt;/=7/10 at the time of enrollment&#xD;
&#xD;
          2. Supplemental oxygen requirement &gt;6 L per minute&#xD;
&#xD;
          3. Delirium (i.e. Memorial delirium rating scale &gt;13)&#xD;
&#xD;
          4. History of unstable angina or myocardial infarction 1 month prior to study enrollment&#xD;
&#xD;
          5. Resting heart rate &gt;120 at the time of study enrollment&#xD;
&#xD;
          6. Systolic pressure &gt;180 mmHg or diastolic pressure &gt;100 mmHg at the time of study&#xD;
             enrollment&#xD;
&#xD;
          7. History of active opioid abuse within the past 12 months&#xD;
&#xD;
          8. History of allergy to fentanyl&#xD;
&#xD;
          9. Severe anemia (Hb &lt;7g/L) if documented in the last month and not corrected prior to&#xD;
             study enrollment*&#xD;
&#xD;
         10. Bilirubin &gt;5X Upper limit of normal if documented in the last month and not lowered to&#xD;
             &lt;5x normal prior to study enrollment*&#xD;
&#xD;
         11. Diagnosis of acute pulmonary embolism within past 2 weeks&#xD;
&#xD;
         12. Diagnosis of pulmonary hypertension&#xD;
&#xD;
         13. Unwilling to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hui, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <results_first_submitted>July 31, 2020</results_first_submitted>
  <results_first_submitted_qc>September 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Cancers</keyword>
  <keyword>Cancer with evidence of active disease</keyword>
  <keyword>Exercise induced breakthrough dyspnea</keyword>
  <keyword>Shortness of breath</keyword>
  <keyword>Fentanyl Buccal Tablets</keyword>
  <keyword>FBT</keyword>
  <keyword>Placebo</keyword>
  <keyword>Walk tests</keyword>
  <keyword>Questionnaires</keyword>
  <keyword>Surveys</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01856114/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult participants (age&gt;18) with an active diagnosis of cancer were recruited between May 2014 to May 2016 from the Supportive Care Center outpatient clinic of MD Anderson Cancer Center who met the inclusion and exclusion criteria.</recruitment_details>
      <pre_assignment_details>A total of 36 participants enrolled. 22 patients were randomized, 14 patients dropped out before randomization, 3 participants died, 4 had declining Karnofsky Performance Score/hospice, 2 participant's Morphine equivalent daily dose was no longer in range, 1 participant declined and 4 participants were no longer interested in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group (Fentanyl Buccal Tablet)</title>
          <description>Received Fentanyl Buccal Tablet 30 minutes before 2nd 6 minute walk test, dose equivalent to 20-50% of their total opioid dose over the past 24 hours.</description>
        </group>
        <group group_id="P2">
          <title>Controlled Group (Placebo)</title>
          <description>Received Placebo tablet 30 minutes before 2nd 6 minute walk test.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The data provided is for the 20 participants that completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group (Fentanyl Buccal Tablet)</title>
          <description>Received Fentanyl Buccal Tablet 30 minutes before 2nd 6 minute walk test, dose equivalent to 20-50% of their total opioid dose over the past 24 hours.</description>
        </group>
        <group group_id="B2">
          <title>Controlled Group (Placebo)</title>
          <description>Received Placebo tablet 30 minutes before 2nd 6 minute walk test.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="31" upper_limit="67"/>
                    <measurement group_id="B2" value="57" lower_limit="45" upper_limit="72"/>
                    <measurement group_id="B3" value="55" lower_limit="31" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>High School or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College and above</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Stage</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Metastatic Stage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally Advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lung Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genitourinary Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gynecologic Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dyspnea Numeric Rating Scale</title>
        <description>Our primary outcome was dyspnea intensity &quot;now&quot; using a dyspnea numeric rating scale that ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). Measured the mean difference between the baseline and second 6 minute walk test. 6 minute walk tests were carried out following guidelines from the American Thoracic Society.</description>
        <time_frame>Baseline to 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (Fentanyl Buccal Tablet)</title>
            <description>Received Fentanyl Buccal Tablet 30 minutes before 2nd 6 minute walk test, dose equivalent to 20-50% of their total opioid dose over the past 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Controlled Group (Placebo)</title>
            <description>Received Placebo tablet 30 minutes before 2nd 6 minute walk test.</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea Numeric Rating Scale</title>
          <description>Our primary outcome was dyspnea intensity &quot;now&quot; using a dyspnea numeric rating scale that ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). Measured the mean difference between the baseline and second 6 minute walk test. 6 minute walk tests were carried out following guidelines from the American Thoracic Society.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-3.5" upper_limit="-1.3"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-2.5" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea Borg Scale</title>
        <description>Assessed dyspnea using the 0-10 modified Dyspnea Borg Scale at baseline walk test and after second 6 minute walk test. The Borg scale ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). Measured the mean difference between the baseline walk test and second 6 minute walk test.</description>
        <time_frame>Baseline to 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (Fentanyl Buccal Tablet)</title>
            <description>Received Fentanyl Buccal Tablet 30 minutes before 2nd 6 minute walk test, dose equivalent to 20-50% of their total opioid dose over the past 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Controlled Group (Placebo)</title>
            <description>Received Placebo tablet 30 minutes before 2nd 6 minute walk test.</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea Borg Scale</title>
          <description>Assessed dyspnea using the 0-10 modified Dyspnea Borg Scale at baseline walk test and after second 6 minute walk test. The Borg scale ranges from 0 (&quot;no shortness of breath&quot;) to 10 (&quot;worst possible shortness of breath&quot;). Measured the mean difference between the baseline walk test and second 6 minute walk test.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-2.9" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-1.9" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walk Distance at 6 Minutes</title>
        <description>Measured the mean difference between the baseline walk test and second 6 minute walk test.</description>
        <time_frame>Baseline to 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group (Fentanyl Buccal Tablet)</title>
            <description>Received Fentanyl Buccal Tablet 30 minutes before 2nd 6 minute walk test, dose equivalent to 20-50% of their total opioid dose over the past 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Controlled Group (Placebo)</title>
            <description>Received Placebo tablet 30 minutes before 2nd 6 minute walk test.</description>
          </group>
        </group_list>
        <measure>
          <title>Walk Distance at 6 Minutes</title>
          <description>Measured the mean difference between the baseline walk test and second 6 minute walk test.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-22.3" upper_limit="20.3"/>
                    <measurement group_id="O2" value="6.7" lower_limit="-3.4" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each adverse effect was measured using an 11-point numeric rating scale (0=none, 10=worst) immediate before drug administration and immediately after the second 6 minute walk test (approximately 30 minutes later).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group (Fentanyl Buccal Tablet)</title>
          <description>Received Fentanyl Buccal Tablet 30 minutes before 2nd 6 minute walk test, dose equivalent to 20-50% of their total opioid dose over the past 24 hours.</description>
        </group>
        <group group_id="E2">
          <title>Controlled Group (Placebo)</title>
          <description>Received Placebo tablet 30 minutes before 2nd 6 minute walk test.&#xD;
.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Drowsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itchiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Hui, MD, Associate Professor, Palliative Care Medicine</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-6258</phone>
      <email>dhui@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

